Literature DB >> 29528896

Toward personalized treatment of hallucinations.

Iris E Sommer1,2,3, Hidde Kleijer1,2, Kenneth Hugdahl3,4,5.   

Abstract

PURPOSE OF REVIEW: Hallucinations are common and often stressful experiences, occurring in all sensory modalities. They frequently complicate many disorders or situations, such as Parkinson's disease, schizophrenia, hearing or vision loss, intoxications and delirium. Although psychoeducation, coping techniques and psychotherapy may be broadly applicable, they do not address a specific underlying brain mechanism. Pharmacotherapy may effectively alleviate hallucinations if the corresponding mechanism is present, whereas in its absence, may only cause harmful side effects. Therefore, pharmacotherapy needs input about underlying brain mechanisms. RECENT
FINDINGS: Recent findings suggest new underlying neurobiological mechanisms as possible therapeutic targets in selected patients, for example increased glutamate levels. In addition, neuronavigation can guide repetitive transcranial magnetic stimulation treatment of auditory verbal hallucinations to target-specific cortical regions.
SUMMARY: We propose the use of neuroimaging methods to better understand the interaction of different mechanisms underlying hallucinations and to use this knowledge to guide pharmacotherapy or focal brain stimulation in a personalized manner. In addition, we suggest evidence from various imaging modalities should converge to answer a research question. We believe this 'convergence of evidence' avoids the problem of overreliance on single and isolated findings.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29528896     DOI: 10.1097/YCO.0000000000000416

Source DB:  PubMed          Journal:  Curr Opin Psychiatry        ISSN: 0951-7367            Impact factor:   4.741


  12 in total

1.  Successful treatment of intractable visual hallucinations with 5-HT 2A antagonist ketanserin.

Authors:  Iris E C Sommer; Hidde Kleijer; Lucy Visser; Teus van Laar
Journal:  BMJ Case Rep       Date:  2018-06-27

2.  Occurrence and phenomenology of hallucinations in the general population: A large online survey.

Authors:  Mascha M J Linszen; Janna N de Boer; Maya J L Schutte; Marieke J H Begemann; Jacqueline de Vries; Sanne Koops; Renske E Blom; Marc M Bohlken; Sophie M Heringa; Jan Dirk Blom; Iris E C Sommer
Journal:  Schizophrenia (Heidelb)       Date:  2022-04-23

3.  Change in the Neural Response to Auditory Deviance Following Cognitive Therapy for Hallucinations in Patients With Schizophrenia.

Authors:  Verner Knott; Nicola Wright; Dhrasti Shah; Ashley Baddeley; Hayley Bowers; Sara de la Salle; Alain Labelle
Journal:  Front Psychiatry       Date:  2020-06-12       Impact factor: 4.157

4.  Aberrant resting-state oscillatory brain activity in Parkinson's disease patients with visual hallucinations: An MEG source-space study.

Authors:  M Dauwan; J I Hoff; E M Vriens; A Hillebrand; C J Stam; I E Sommer
Journal:  Neuroimage Clin       Date:  2019-03-13       Impact factor: 4.881

Review 5.  Auditory verbal hallucinations in schizophrenia: current perspectives in brain stimulation treatments.

Authors:  Clément Nathou; Olivier Etard; Sonia Dollfus
Journal:  Neuropsychiatr Dis Treat       Date:  2019-07-24       Impact factor: 2.570

6.  Exploring neuroimaging-genetic co-alteration features of auditory verbal hallucinations in different subjects for the establishment of a predictive model.

Authors:  Lang-Lang Cheng; Guo-Wei Wang; Yan-Chi Zhang; Gong-Ying Li; Hong-Jun Tian; Li-Na Wang; Xiu-Hai Sun; Chun-Hua Zhou; Chuan-Jun Zhuo
Journal:  Chin Med J (Engl)       Date:  2019-09-05       Impact factor: 2.628

Review 7.  The Pharmacology of Visual Hallucinations in Synucleinopathies.

Authors:  Mirella Russo; Claudia Carrarini; Fedele Dono; Marianna Gabriella Rispoli; Martina Di Pietro; Vincenzo Di Stefano; Laura Ferri; Laura Bonanni; Stefano Luca Sensi; Marco Onofrj
Journal:  Front Pharmacol       Date:  2019-12-09       Impact factor: 5.810

8.  Understanding hallucinations in probable Alzheimer's disease: Very low prevalence rates in a tertiary memory clinic.

Authors:  Mascha M J Linszen; Afina W Lemstra; Meenakshi Dauwan; Rachel M Brouwer; Philip Scheltens; Iris E C Sommer
Journal:  Alzheimers Dement (Amst)       Date:  2018-04-21

9.  Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis.

Authors:  Igne Sinkeviciute; Marieke Begemann; Merel Prikken; Bob Oranje; Erik Johnsen; Wan U Lei; Kenneth Hugdahl; Rune A Kroken; Carina Rau; Jolien D Jacobs; Silvia Mattaroccia; Iris E Sommer
Journal:  NPJ Schizophr       Date:  2018-10-25

10.  Auditory hallucinations, top-down processing and language perception: a general population study.

Authors:  J N de Boer; M M J Linszen; J de Vries; M J L Schutte; M J H Begemann; S M Heringa; M M Bohlken; K Hugdahl; A Aleman; F N K Wijnen; I E C Sommer
Journal:  Psychol Med       Date:  2019-01-04       Impact factor: 7.723

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.